SURG vs. ZIMV, SNWV, CATX, NYXH, DRTS, SMTI, BWAY, SKIN, TCMD, and STIM
Should you be buying SurgePays stock or one of its competitors? The main competitors of SurgePays include ZimVie (ZIMV), Sanuwave Health (SNWV), Perspective Therapeutics (CATX), Nyxoah (NYXH), Alpha Tau Medical (DRTS), Sanara MedTech (SMTI), Brainsway (BWAY), Beauty Health (SKIN), Tactile Systems Technology (TCMD), and Neuronetics (STIM). These companies are all part of the "medical equipment" industry.
SurgePays vs. Its Competitors
ZimVie (NASDAQ:ZIMV) and SurgePays (NASDAQ:SURG) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.
95.6% of ZimVie shares are owned by institutional investors. Comparatively, 6.9% of SurgePays shares are owned by institutional investors. 5.4% of ZimVie shares are owned by company insiders. Comparatively, 30.5% of SurgePays shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, SurgePays had 1 more articles in the media than ZimVie. MarketBeat recorded 1 mentions for SurgePays and 0 mentions for ZimVie. SurgePays' average media sentiment score of 0.20 beat ZimVie's score of 0.00 indicating that SurgePays is being referred to more favorably in the news media.
ZimVie has higher revenue and earnings than SurgePays. ZimVie is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.
ZimVie has a net margin of -4.40% compared to SurgePays' net margin of -136.37%. ZimVie's return on equity of 5.53% beat SurgePays' return on equity.
ZimVie currently has a consensus price target of $16.33, indicating a potential upside of 73.21%. SurgePays has a consensus price target of $9.00, indicating a potential upside of 172.73%. Given SurgePays' stronger consensus rating and higher possible upside, analysts clearly believe SurgePays is more favorable than ZimVie.
ZimVie has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500. Comparatively, SurgePays has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500.
Summary
ZimVie beats SurgePays on 9 of the 17 factors compared between the two stocks.
Get SurgePays News Delivered to You Automatically
Sign up to receive the latest news and ratings for SURG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SURG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SurgePays Competitors List
Related Companies and Tools
This page (NASDAQ:SURG) was last updated on 7/8/2025 by MarketBeat.com Staff
Free SURG Stock Alerts